Myelofibrosis echocardiography or ultrasound: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Bot: Removing from Primary care)
 
(4 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Myelofibrosis}}
{{Myelofibrosis}}
{{CMG}}
{{CMG}}{{AE}}{{Sab}}


==Overview==
==Overview==
There are no echocardiography/ultrasound findings associated with myelofibrosis. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of myelofibrosis, which include heart failure, splenic rupture, pulmonary hypertension, intestinal obstruction, splenomegaly, hepatomegaly, ureteral obstruction, and thrombotic events.
There are no [[echocardiography]]/[[ultrasound]] findings associated with [[myelofibrosis]]. However, an [[echocardiography]]/[[ultrasound]] may be helpful in the [[diagnosis]] of [[Complication (medicine)|complications]] of [[myelofibrosis]], which include [[heart failure]], [[splenic rupture]], [[pulmonary hypertension]], [[Bowel obstruction|intestinal obstruction]], [[splenomegaly]], [[hepatomegaly]], [[ureteral obstruction]], and [[Thrombosis|thrombotic]] events.


==Echocardiography/Ultrasound==
==Echocardiography/Ultrasound==
There are no echocardiography/ultrasound findings associated with myelofibrosis. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of myelofibrosis, which include:
There are no [[echocardiography]]/[[ultrasound]] findings associated with [[myelofibrosis]]. However, an [[echocardiography]]/[[ultrasound]] may be helpful in the [[diagnosis]] of [[Complication (medicine)|complications]] of [[myelofibrosis]], which include:
*Heart failure<ref name="pmid18160817">{{cite journal |vauthors=Guilpain P, Montani D, Damaj G, Achouh L, Lefrère F, Le Pavec J, Marfaing-Koka A, Dartevelle P, Simonneau G, Humbert M, Hermine O |title=Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases |journal=Respiration |volume=76 |issue=3 |pages=295–302 |date=2008 |pmid=18160817 |doi=10.1159/000112822 |url=}}</ref><ref name="pmid9929105">{{cite journal |vauthors=García-Manero G, Schuster SJ, Patrick H, Martinez J |title=Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases |journal=Am. J. Hematol. |volume=60 |issue=2 |pages=130–5 |date=February 1999 |pmid=9929105 |doi= |url=}}</ref>
*[[Heart failure]]<ref name="pmid18160817">{{cite journal |vauthors=Guilpain P, Montani D, Damaj G, Achouh L, Lefrère F, Le Pavec J, Marfaing-Koka A, Dartevelle P, Simonneau G, Humbert M, Hermine O |title=Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases |journal=Respiration |volume=76 |issue=3 |pages=295–302 |date=2008 |pmid=18160817 |doi=10.1159/000112822 |url=}}</ref><ref name="pmid9929105">{{cite journal |vauthors=García-Manero G, Schuster SJ, Patrick H, Martinez J |title=Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases |journal=Am. J. Hematol. |volume=60 |issue=2 |pages=130–5 |date=February 1999 |pmid=9929105 |doi= |url=}}</ref>
*Splenomegaly<ref name="pmid27349913">{{cite journal |vauthors=Song MK, Chung JS, Lim SN, Lee GW, Lee SM, Lee NK, Choi JC, Oh SY |title=Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis |journal=Int. J. Hematol. |volume=104 |issue=4 |pages=476–84 |date=October 2016 |pmid=27349913 |doi=10.1007/s12185-016-2050-y |url=}}</ref><ref name="pmid24929265">{{cite journal |vauthors=Orphanidou-Vlachou E, Tziakouri-Shiakalli C, Georgiades CS |title=Extramedullary hemopoiesis |journal=Semin. Ultrasound CT MR |volume=35 |issue=3 |pages=255–62 |date=June 2014 |pmid=24929265 |doi=10.1053/j.sult.2013.12.001 |url=}}</ref><ref name="pmid16642932">{{cite journal |vauthors=Ito A, Umeda M, Koike T, Naruse S, Fujita N |title=[A case of dermatomyositis associated with chronic idiopathic myelofibrosis] |language=Japanese |journal=Rinsho Shinkeigaku |volume=46 |issue=3 |pages=210–3 |date=March 2006 |pmid=16642932 |doi= |url=}}</ref><ref name="pmid2925932">{{cite journal |vauthors=Kobayashi A, Sugihara M, Kurosaki M, Ishida Y, Takayanagi N, Matsui O, Takashima T |title=CT characteristics of intrahepatic, periportal, extramedullary hematopoiesis |journal=J Comput Assist Tomogr |volume=13 |issue=2 |pages=354–6 |date=1989 |pmid=2925932 |doi= |url=}}</ref>
*[[Splenomegaly]]<ref name="pmid27349913">{{cite journal |vauthors=Song MK, Chung JS, Lim SN, Lee GW, Lee SM, Lee NK, Choi JC, Oh SY |title=Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis |journal=Int. J. Hematol. |volume=104 |issue=4 |pages=476–84 |date=October 2016 |pmid=27349913 |doi=10.1007/s12185-016-2050-y |url=}}</ref><ref name="pmid24929265">{{cite journal |vauthors=Orphanidou-Vlachou E, Tziakouri-Shiakalli C, Georgiades CS |title=Extramedullary hemopoiesis |journal=Semin. Ultrasound CT MR |volume=35 |issue=3 |pages=255–62 |date=June 2014 |pmid=24929265 |doi=10.1053/j.sult.2013.12.001 |url=}}</ref><ref name="pmid16642932">{{cite journal |vauthors=Ito A, Umeda M, Koike T, Naruse S, Fujita N |title=[A case of dermatomyositis associated with chronic idiopathic myelofibrosis] |language=Japanese |journal=Rinsho Shinkeigaku |volume=46 |issue=3 |pages=210–3 |date=March 2006 |pmid=16642932 |doi= |url=}}</ref><ref name="pmid2925932">{{cite journal |vauthors=Kobayashi A, Sugihara M, Kurosaki M, Ishida Y, Takayanagi N, Matsui O, Takashima T |title=CT characteristics of intrahepatic, periportal, extramedullary hematopoiesis |journal=J Comput Assist Tomogr |volume=13 |issue=2 |pages=354–6 |date=1989 |pmid=2925932 |doi= |url=}}</ref>
*Hepatomegaly<ref name="pmid24929265">{{cite journal |vauthors=Orphanidou-Vlachou E, Tziakouri-Shiakalli C, Georgiades CS |title=Extramedullary hemopoiesis |journal=Semin. Ultrasound CT MR |volume=35 |issue=3 |pages=255–62 |date=June 2014 |pmid=24929265 |doi=10.1053/j.sult.2013.12.001 |url=}}</ref><ref name="pmid22470696">{{cite journal |vauthors=La Fianza A, van der Byl G, Maccabelli G, Torretta L, Calliada F |title=CT and MR findings in extramedullary haematopoiesis with biliary system encasement: a case report |journal=J Radiol Case Rep |volume=4 |issue=11 |pages=1–8 |date=2010 |pmid=22470696 |pmc=3303353 |doi=10.3941/jrcr.v4i11.462 |url=}}</ref><ref name="pmid10983698">{{cite journal |vauthors=Kwak HS, Lee JM |title=CT findings of extramedullary hematopoiesis in the thorax, liver and kidneys, in a patient with idiopathic myelofibrosis |journal=J. Korean Med. Sci. |volume=15 |issue=4 |pages=460–2 |date=August 2000 |pmid=10983698 |pmc=3054659 |doi=10.3346/jkms.2000.15.4.460 |url=}}</ref><ref name="pmid2925932">{{cite journal |vauthors=Kobayashi A, Sugihara M, Kurosaki M, Ishida Y, Takayanagi N, Matsui O, Takashima T |title=CT characteristics of intrahepatic, periportal, extramedullary hematopoiesis |journal=J Comput Assist Tomogr |volume=13 |issue=2 |pages=354–6 |date=1989 |pmid=2925932 |doi= |url=}}</ref>
*[[Hepatomegaly]]<ref name="pmid24929265">{{cite journal |vauthors=Orphanidou-Vlachou E, Tziakouri-Shiakalli C, Georgiades CS |title=Extramedullary hemopoiesis |journal=Semin. Ultrasound CT MR |volume=35 |issue=3 |pages=255–62 |date=June 2014 |pmid=24929265 |doi=10.1053/j.sult.2013.12.001 |url=}}</ref><ref name="pmid22470696">{{cite journal |vauthors=La Fianza A, van der Byl G, Maccabelli G, Torretta L, Calliada F |title=CT and MR findings in extramedullary haematopoiesis with biliary system encasement: a case report |journal=J Radiol Case Rep |volume=4 |issue=11 |pages=1–8 |date=2010 |pmid=22470696 |pmc=3303353 |doi=10.3941/jrcr.v4i11.462 |url=}}</ref><ref name="pmid10983698">{{cite journal |vauthors=Kwak HS, Lee JM |title=CT findings of extramedullary hematopoiesis in the thorax, liver and kidneys, in a patient with idiopathic myelofibrosis |journal=J. Korean Med. Sci. |volume=15 |issue=4 |pages=460–2 |date=August 2000 |pmid=10983698 |pmc=3054659 |doi=10.3346/jkms.2000.15.4.460 |url=}}</ref><ref name="pmid2925932">{{cite journal |vauthors=Kobayashi A, Sugihara M, Kurosaki M, Ishida Y, Takayanagi N, Matsui O, Takashima T |title=CT characteristics of intrahepatic, periportal, extramedullary hematopoiesis |journal=J Comput Assist Tomogr |volume=13 |issue=2 |pages=354–6 |date=1989 |pmid=2925932 |doi= |url=}}</ref>
*Splenic rupture<ref name="pmid22096219">{{cite journal |vauthors=Saboo SS, Krajewski KM, O'Regan KN, Giardino A, Brown JR, Ramaiya N, Jagannathan JP |title=Spleen in haematological malignancies: spectrum of imaging findings |journal=Br J Radiol |volume=85 |issue=1009 |pages=81–92 |date=January 2012 |pmid=22096219 |pmc=3473934 |doi=10.1259/bjr/31542964 |url=}}</ref><ref name="pmid2395215">{{cite journal |vauthors=Baba M, Tanahashi N, Seno K, Nara M, Shinbo T |title=[Myelofibrosis with marked subcapsular bleeding of the spleen--a case report] |language=Japanese |journal=Rinsho Ketsueki |volume=31 |issue=5 |pages=669–73 |date=May 1990 |pmid=2395215 |doi= |url=}}</ref>
*[[Splenic rupture]]<ref name="pmid22096219">{{cite journal |vauthors=Saboo SS, Krajewski KM, O'Regan KN, Giardino A, Brown JR, Ramaiya N, Jagannathan JP |title=Spleen in haematological malignancies: spectrum of imaging findings |journal=Br J Radiol |volume=85 |issue=1009 |pages=81–92 |date=January 2012 |pmid=22096219 |pmc=3473934 |doi=10.1259/bjr/31542964 |url=}}</ref><ref name="pmid2395215">{{cite journal |vauthors=Baba M, Tanahashi N, Seno K, Nara M, Shinbo T |title=[Myelofibrosis with marked subcapsular bleeding of the spleen--a case report] |language=Japanese |journal=Rinsho Ketsueki |volume=31 |issue=5 |pages=669–73 |date=May 1990 |pmid=2395215 |doi= |url=}}</ref>
*Pulmonary hypertension<ref name="pmid28680586">{{cite journal |vauthors=Singh I, Mikita G, Green D, Risquez C, Sanders A |title=Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series |journal=Pulm Circ |volume=7 |issue=1 |pages=261–267 |date=March 2017 |pmid=28680586 |pmc=5448544 |doi=10.1177/2045893217702064 |url=}}</ref><ref name="pmid28090305">{{cite journal |vauthors=Faiz SA, Iliescu C, Lopez-Mattei J, Patel B, Bashoura L, Popat U |title=Resolution of myelofibrosis-associated pulmonary arterial hypertension following allogeneic hematopoietic stem cell transplantation |journal=Pulm Circ |volume=6 |issue=4 |pages=611–613 |date=December 2016 |pmid=28090305 |pmc=5210054 |doi=10.1086/687291 |url=}}</ref><ref name="pmid28070238">{{cite journal |vauthors=Mathew R, Huang J, Wu JM, Fallon JT, Gewitz MH |title=Hematological disorders and pulmonary hypertension |journal=World J Cardiol |volume=8 |issue=12 |pages=703–718 |date=December 2016 |pmid=28070238 |pmc=5183970 |doi=10.4330/wjc.v8.i12.703 |url=}}</ref>
*[[Pulmonary hypertension]]<ref name="pmid28680586">{{cite journal |vauthors=Singh I, Mikita G, Green D, Risquez C, Sanders A |title=Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series |journal=Pulm Circ |volume=7 |issue=1 |pages=261–267 |date=March 2017 |pmid=28680586 |pmc=5448544 |doi=10.1177/2045893217702064 |url=}}</ref><ref name="pmid28090305">{{cite journal |vauthors=Faiz SA, Iliescu C, Lopez-Mattei J, Patel B, Bashoura L, Popat U |title=Resolution of myelofibrosis-associated pulmonary arterial hypertension following allogeneic hematopoietic stem cell transplantation |journal=Pulm Circ |volume=6 |issue=4 |pages=611–613 |date=December 2016 |pmid=28090305 |pmc=5210054 |doi=10.1086/687291 |url=}}</ref><ref name="pmid28070238">{{cite journal |vauthors=Mathew R, Huang J, Wu JM, Fallon JT, Gewitz MH |title=Hematological disorders and pulmonary hypertension |journal=World J Cardiol |volume=8 |issue=12 |pages=703–718 |date=December 2016 |pmid=28070238 |pmc=5183970 |doi=10.4330/wjc.v8.i12.703 |url=}}</ref>
*Intestinal obstruction<ref name="pmid25206301">{{cite journal |vauthors=Wei XQ, Zheng ZH, Jin Y, Tao J, Abassa KK, Wen ZF, Shao CK, Wei HB, Wu B |title=Intestinal obstruction caused by extramedullary hematopoiesis and ascites in primary myelofibrosis |journal=World J. Gastroenterol. |volume=20 |issue=33 |pages=11921–6 |date=September 2014 |pmid=25206301 |pmc=4155387 |doi=10.3748/wjg.v20.i33.11921 |url=}}</ref>
*[[Bowel obstruction|Intestinal obstruction]]<ref name="pmid25206301">{{cite journal |vauthors=Wei XQ, Zheng ZH, Jin Y, Tao J, Abassa KK, Wen ZF, Shao CK, Wei HB, Wu B |title=Intestinal obstruction caused by extramedullary hematopoiesis and ascites in primary myelofibrosis |journal=World J. Gastroenterol. |volume=20 |issue=33 |pages=11921–6 |date=September 2014 |pmid=25206301 |pmc=4155387 |doi=10.3748/wjg.v20.i33.11921 |url=}}</ref>
*Thrombotic events<ref name="pmid29946154">{{cite journal |vauthors=Finazzi G, De Stefano V, Barbui T |title=Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018 |journal=Blood Cancer J |volume=8 |issue=7 |pages=64 |date=June 2018 |pmid=29946154 |pmc=6018786 |doi=10.1038/s41408-018-0100-9 |url=}}</ref><ref name="pmid29368941">{{cite journal |vauthors=Sández Montagut VM, Giráldez Gallego Á, Ontanilla Clavijo G |title=Regenerative nodular hyperplasia, portal vein thrombosis and primary myelofibrosis: an unusual triple association |journal=Rev Esp Enferm Dig |volume=110 |issue=3 |pages=209–210 |date=March 2018 |pmid=29368941 |doi=10.17235/reed.2018.5349/2017 |url=}}</ref><ref name="pmid29048104">{{cite journal |vauthors=How J, Trinkaus KM, Oh ST |title=Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis |journal=Br. J. Haematol. |volume=183 |issue=2 |pages=310–313 |date=October 2018 |pmid=29048104 |doi=10.1111/bjh.14958 |url=}}</ref><ref name="pmid28991281">{{cite journal |vauthors=Campos-Cabrera G, Campos-Cabrera V, Campos-Cabrera S, Campos-Villagómez JL, Romero-González A |title=Splanchnic vein thrombosis as a first manifestation of Primary myelofibrosis |language=Spanish; Castilian |journal=Gac Med Mex |volume=153 |issue=4 |pages=537–540 |date=2017 |pmid=28991281 |doi=10.24875/GMM.17002822 |url=}}</ref><ref name="pmid28808761">{{cite journal |vauthors=Kc D, Falchi L, Verstovsek S |title=The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review |journal=Ann. Hematol. |volume=96 |issue=10 |pages=1595–1604 |date=October 2017 |pmid=28808761 |pmc=5693670 |doi=10.1007/s00277-017-3099-2 |url=}}</ref>  
*[[Thrombosis|Thrombotic events]]<ref name="pmid29946154">{{cite journal |vauthors=Finazzi G, De Stefano V, Barbui T |title=Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018 |journal=Blood Cancer J |volume=8 |issue=7 |pages=64 |date=June 2018 |pmid=29946154 |pmc=6018786 |doi=10.1038/s41408-018-0100-9 |url=}}</ref><ref name="pmid29368941">{{cite journal |vauthors=Sández Montagut VM, Giráldez Gallego Á, Ontanilla Clavijo G |title=Regenerative nodular hyperplasia, portal vein thrombosis and primary myelofibrosis: an unusual triple association |journal=Rev Esp Enferm Dig |volume=110 |issue=3 |pages=209–210 |date=March 2018 |pmid=29368941 |doi=10.17235/reed.2018.5349/2017 |url=}}</ref><ref name="pmid29048104">{{cite journal |vauthors=How J, Trinkaus KM, Oh ST |title=Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis |journal=Br. J. Haematol. |volume=183 |issue=2 |pages=310–313 |date=October 2018 |pmid=29048104 |doi=10.1111/bjh.14958 |url=}}</ref><ref name="pmid28991281">{{cite journal |vauthors=Campos-Cabrera G, Campos-Cabrera V, Campos-Cabrera S, Campos-Villagómez JL, Romero-González A |title=Splanchnic vein thrombosis as a first manifestation of Primary myelofibrosis |language=Spanish; Castilian |journal=Gac Med Mex |volume=153 |issue=4 |pages=537–540 |date=2017 |pmid=28991281 |doi=10.24875/GMM.17002822 |url=}}</ref><ref name="pmid28808761">{{cite journal |vauthors=Kc D, Falchi L, Verstovsek S |title=The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review |journal=Ann. Hematol. |volume=96 |issue=10 |pages=1595–1604 |date=October 2017 |pmid=28808761 |pmc=5693670 |doi=10.1007/s00277-017-3099-2 |url=}}</ref>  
*Ureteral obstruction<ref name="pmid20949707">{{cite journal |vauthors=Cvetković ZP, Cvetković BR, Celeketić D, Milenković D, Perunicić-Peković G |title=Bilateral ureteral obstruction due to primary myelofibrosis caused hyperuricaemia |journal=Acta Chir Iugosl |volume=57 |issue=2 |pages=79–83 |date=2010 |pmid=20949707 |doi= |url=}}</ref>
*[[Ureteral obstruction]]<ref name="pmid20949707">{{cite journal |vauthors=Cvetković ZP, Cvetković BR, Celeketić D, Milenković D, Perunicić-Peković G |title=Bilateral ureteral obstruction due to primary myelofibrosis caused hyperuricaemia |journal=Acta Chir Iugosl |volume=57 |issue=2 |pages=79–83 |date=2010 |pmid=20949707 |doi= |url=}}</ref>
*Ascites<ref name="pmid2925932">{{cite journal |vauthors=Kobayashi A, Sugihara M, Kurosaki M, Ishida Y, Takayanagi N, Matsui O, Takashima T |title=CT characteristics of intrahepatic, periportal, extramedullary hematopoiesis |journal=J Comput Assist Tomogr |volume=13 |issue=2 |pages=354–6 |date=1989 |pmid=2925932 |doi= |url=}}</ref>
*[[Ascites]]<ref name="pmid2925932">{{cite journal |vauthors=Kobayashi A, Sugihara M, Kurosaki M, Ishida Y, Takayanagi N, Matsui O, Takashima T |title=CT characteristics of intrahepatic, periportal, extramedullary hematopoiesis |journal=J Comput Assist Tomogr |volume=13 |issue=2 |pages=354–6 |date=1989 |pmid=2925932 |doi= |url=}}</ref>
 
==References==
{{reflist|2}}
 
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Oncology]]
[[Category:Neurology]]
[[Category:Neurosurgery]]
[[Category:Up-To-Date]]

Latest revision as of 22:50, 29 July 2020

Myelofibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelofibrosis echocardiography or ultrasound On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelofibrosis echocardiography or ultrasound

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelofibrosis echocardiography or ultrasound

CDC on Myelofibrosis echocardiography or ultrasound

Myelofibrosis echocardiography or ultrasound in the news

Blogs on Myelofibrosis echocardiography or ultrasound

Directions to Hospitals Treating Myelofibrosis

Risk calculators and risk factors for Myelofibrosis echocardiography or ultrasound

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]

Overview

There are no echocardiography/ultrasound findings associated with myelofibrosis. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of myelofibrosis, which include heart failure, splenic rupture, pulmonary hypertension, intestinal obstruction, splenomegaly, hepatomegaly, ureteral obstruction, and thrombotic events.

Echocardiography/Ultrasound

There are no echocardiography/ultrasound findings associated with myelofibrosis. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of myelofibrosis, which include:

References

  1. ↑ Guilpain P, Montani D, Damaj G, Achouh L, Lefrère F, Le Pavec J, Marfaing-Koka A, Dartevelle P, Simonneau G, Humbert M, Hermine O (2008). "Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases". Respiration. 76 (3): 295–302. doi:10.1159/000112822. PMID 18160817.
  2. ↑ García-Manero G, Schuster SJ, Patrick H, Martinez J (February 1999). "Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases". Am. J. Hematol. 60 (2): 130–5. PMID 9929105.
  3. ↑ Song MK, Chung JS, Lim SN, Lee GW, Lee SM, Lee NK, Choi JC, Oh SY (October 2016). "Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis". Int. J. Hematol. 104 (4): 476–84. doi:10.1007/s12185-016-2050-y. PMID 27349913.
  4. ↑ 4.0 4.1 Orphanidou-Vlachou E, Tziakouri-Shiakalli C, Georgiades CS (June 2014). "Extramedullary hemopoiesis". Semin. Ultrasound CT MR. 35 (3): 255–62. doi:10.1053/j.sult.2013.12.001. PMID 24929265.
  5. ↑ Ito A, Umeda M, Koike T, Naruse S, Fujita N (March 2006). "[A case of dermatomyositis associated with chronic idiopathic myelofibrosis]". Rinsho Shinkeigaku (in Japanese). 46 (3): 210–3. PMID 16642932.
  6. ↑ 6.0 6.1 6.2 Kobayashi A, Sugihara M, Kurosaki M, Ishida Y, Takayanagi N, Matsui O, Takashima T (1989). "CT characteristics of intrahepatic, periportal, extramedullary hematopoiesis". J Comput Assist Tomogr. 13 (2): 354–6. PMID 2925932.
  7. ↑ La Fianza A, van der Byl G, Maccabelli G, Torretta L, Calliada F (2010). "CT and MR findings in extramedullary haematopoiesis with biliary system encasement: a case report". J Radiol Case Rep. 4 (11): 1–8. doi:10.3941/jrcr.v4i11.462. PMC 3303353. PMID 22470696.
  8. ↑ Kwak HS, Lee JM (August 2000). "CT findings of extramedullary hematopoiesis in the thorax, liver and kidneys, in a patient with idiopathic myelofibrosis". J. Korean Med. Sci. 15 (4): 460–2. doi:10.3346/jkms.2000.15.4.460. PMC 3054659. PMID 10983698.
  9. ↑ Saboo SS, Krajewski KM, O'Regan KN, Giardino A, Brown JR, Ramaiya N, Jagannathan JP (January 2012). "Spleen in haematological malignancies: spectrum of imaging findings". Br J Radiol. 85 (1009): 81–92. doi:10.1259/bjr/31542964. PMC 3473934. PMID 22096219.
  10. ↑ Baba M, Tanahashi N, Seno K, Nara M, Shinbo T (May 1990). "[Myelofibrosis with marked subcapsular bleeding of the spleen--a case report]". Rinsho Ketsueki (in Japanese). 31 (5): 669–73. PMID 2395215.
  11. ↑ Singh I, Mikita G, Green D, Risquez C, Sanders A (March 2017). "Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series". Pulm Circ. 7 (1): 261–267. doi:10.1177/2045893217702064. PMC 5448544. PMID 28680586.
  12. ↑ Faiz SA, Iliescu C, Lopez-Mattei J, Patel B, Bashoura L, Popat U (December 2016). "Resolution of myelofibrosis-associated pulmonary arterial hypertension following allogeneic hematopoietic stem cell transplantation". Pulm Circ. 6 (4): 611–613. doi:10.1086/687291. PMC 5210054. PMID 28090305.
  13. ↑ Mathew R, Huang J, Wu JM, Fallon JT, Gewitz MH (December 2016). "Hematological disorders and pulmonary hypertension". World J Cardiol. 8 (12): 703–718. doi:10.4330/wjc.v8.i12.703. PMC 5183970. PMID 28070238.
  14. ↑ Wei XQ, Zheng ZH, Jin Y, Tao J, Abassa KK, Wen ZF, Shao CK, Wei HB, Wu B (September 2014). "Intestinal obstruction caused by extramedullary hematopoiesis and ascites in primary myelofibrosis". World J. Gastroenterol. 20 (33): 11921–6. doi:10.3748/wjg.v20.i33.11921. PMC 4155387. PMID 25206301.
  15. ↑ Finazzi G, De Stefano V, Barbui T (June 2018). "Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018". Blood Cancer J. 8 (7): 64. doi:10.1038/s41408-018-0100-9. PMC 6018786. PMID 29946154.
  16. ↑ Sández Montagut VM, Giráldez Gallego Á, Ontanilla Clavijo G (March 2018). "Regenerative nodular hyperplasia, portal vein thrombosis and primary myelofibrosis: an unusual triple association". Rev Esp Enferm Dig. 110 (3): 209–210. doi:10.17235/reed.2018.5349/2017. PMID 29368941.
  17. ↑ How J, Trinkaus KM, Oh ST (October 2018). "Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis". Br. J. Haematol. 183 (2): 310–313. doi:10.1111/bjh.14958. PMID 29048104.
  18. ↑ Campos-Cabrera G, Campos-Cabrera V, Campos-Cabrera S, Campos-Villagómez JL, Romero-González A (2017). "Splanchnic vein thrombosis as a first manifestation of Primary myelofibrosis". Gac Med Mex (in Spanish; Castilian). 153 (4): 537–540. doi:10.24875/GMM.17002822. PMID 28991281.
  19. ↑ Kc D, Falchi L, Verstovsek S (October 2017). "The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review". Ann. Hematol. 96 (10): 1595–1604. doi:10.1007/s00277-017-3099-2. PMC 5693670. PMID 28808761.
  20. ↑ Cvetković ZP, Cvetković BR, Celeketić D, Milenković D, Perunicić-Peković G (2010). "Bilateral ureteral obstruction due to primary myelofibrosis caused hyperuricaemia". Acta Chir Iugosl. 57 (2): 79–83. PMID 20949707.
Retrieved from "https://www.wikidoc.org/index.php?title=Myelofibrosis_echocardiography_or_ultrasound&oldid=1640978"